Atlas Capital Advisors LLC lifted its stake in shares of CVS Health Corp (NYSE:CVS) by 7,653.0% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,778 shares of the pharmacy operator’s stock after acquiring an additional 20,510 shares during the period. Atlas Capital Advisors LLC’s holdings in CVS Health were worth $1,361,000 as of its most recent SEC filing.
Several other hedge funds also recently made changes to their positions in CVS. Bell Rock Capital LLC lifted its holdings in shares of CVS Health by 764.0% during the 4th quarter. Bell Rock Capital LLC now owns 432 shares of the pharmacy operator’s stock worth $28,000 after acquiring an additional 382 shares during the period. Daiwa SB Investments Ltd. purchased a new position in shares of CVS Health during the 4th quarter worth about $30,000. Cornerstone Advisors Inc. lifted its holdings in shares of CVS Health by 71.6% during the 3rd quarter. Cornerstone Advisors Inc. now owns 508 shares of the pharmacy operator’s stock worth $40,000 after acquiring an additional 212 shares during the period. Avestar Capital LLC lifted its holdings in shares of CVS Health by 19.6% during the 4th quarter. Avestar Capital LLC now owns 951 shares of the pharmacy operator’s stock worth $57,000 after acquiring an additional 156 shares during the period. Finally, Truewealth LLC raised its holdings in CVS Health by 78.6% in the fourth quarter. Truewealth LLC now owns 1,004 shares of the pharmacy operator’s stock valued at $66,000 after buying an additional 442 shares during the period. Institutional investors and hedge funds own 87.22% of the company’s stock.
Shares of NYSE:CVS opened at $67.79 on Thursday. The company has a debt-to-equity ratio of 1.66, a current ratio of 2.44 and a quick ratio of 1.94. CVS Health Corp has a 52-week low of $60.14 and a 52-week high of $82.15. The company has a market capitalization of $66.34 billion, a price-to-earnings ratio of 11.49, a PEG ratio of 0.88 and a beta of 1.03.
The company also recently disclosed a quarterly dividend, which was paid on Monday, February 4th. Shareholders of record on Friday, January 25th were given a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 2.95%. The ex-dividend date was Thursday, January 24th. CVS Health’s dividend payout ratio (DPR) is 33.90%.
In other CVS Health news, CFO David M. Denton sold 25,159 shares of the stock in a transaction that occurred on Thursday, November 29th. The shares were sold at an average price of $80.13, for a total value of $2,015,990.67. Following the completion of the sale, the chief financial officer now owns 403 shares of the company’s stock, valued at $32,292.39. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Larry J. Merlo sold 166,368 shares of the stock in a transaction that occurred on Tuesday, January 8th. The shares were sold at an average price of $69.04, for a total transaction of $11,486,046.72. Following the completion of the sale, the insider now directly owns 496,577 shares of the company’s stock, valued at approximately $34,283,676.08. The disclosure for this sale can be found here. Insiders sold 435,534 shares of company stock valued at $29,245,258 in the last ninety days. 0.53% of the stock is owned by corporate insiders.
Several research analysts recently commented on CVS shares. Cantor Fitzgerald started coverage on shares of CVS Health in a report on Sunday, December 2nd. They issued an “overweight” rating and a $77.84 price target on the stock. ValuEngine upgraded shares of CVS Health from a “sell” rating to a “hold” rating in a report on Tuesday, November 6th. UBS Group started coverage on shares of CVS Health in a report on Thursday, January 17th. They issued a “buy” rating and a $75.00 price target on the stock. Bank of America restated a “buy” rating and issued a $92.00 price target on shares of CVS Health in a report on Thursday, January 3rd. Finally, Loop Capital set a $80.00 price target on shares of CVS Health and gave the company a “hold” rating in a report on Friday, November 9th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have given a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $91.79.
CVS Health Company Profile
CVS Health Corporation, together with its subsidiaries, provides integrated pharmacy health care services. It operates through Pharmacy Services and Retail/LTC segments. The Pharmacy Services segment offers pharmacy benefit management solutions, such as plan design and administration, formulary management, Medicare Part D services, mail order, specialty pharmacy and infusion services, retail pharmacy network management services, prescription management systems, clinical services, disease management programs, and medical pharmacy management services.
Read More: What is a bull market?
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.